The clinical response in this allergy model system validates a new paradigm for developing anti-allergen antibodies for treating allergic diseases: Preclinical selection of potent, fully human anti-allergen antibodies that block allergen binding to a majority of allergen-specific IgE, directly administered to patients for rapid and meaningful symptom relief. This evidence concerns the gene IGHE and Allergy.